In conclusion, patients with co-existing BRAF V600E and TERT promoter mutation have a worse prognosis. ARMS-qPCR,the more sensitive method, can be used to identify the early stages of patients with a potentially worse prognosis
Endocr Pract. 2021 Jan 27;S1530-891X(21)00021-5.
Testing for activating KRAS mutations has important implications for diagnosis and the personalized medicine of cancers.
Diagnostics (Basel). 2021 Jan; 11(1): 125.
Here, we present the case of a 56-year-old man who was diagnosed with lung adenocarcinoma with MET exon 14 skipping mutation.
Cancer Commun. 2021 Jan 2.
Our finding demonstrated that the incidence, not the severity, of gefitinib-induced rash predicted improved survival, the gefitinib concentration and polymorphisms of SLC22A8 and SLC22A1 were recommended to manage severe rash.
Transl Oncol. 2020 Nov 19;14(1):100951.
the ALK-positive tumor microenvironment suppresses the immune function of tumor-infiltrating CD8+ T cells through a PD-1/PD-L1-independent mechanism, which might lead to the inability of ALK-positive tumors to respond to PD-1/PD-L1-based immunotherapy.
Lung Cancer. 2020 Oct 21;150:139-144.
Analyzing mutations in plasma could provide a more comprehensive overview of the mutational landscape than analyzing mutations in tissue. The cfDNA concentration could be a quantitative biomarker of tumor burden and could predict survival in Chinese patients with mCRC
BMC Cancer. 2020 Oct 16;20(1):1006.